IBM Delivers New Qualified mySAP All-in-One Solution for Pharmaceutical Industry
Fixed Price and Rapid Implementation Time Tailored for Growing Companies Navigating Regulatory Mandates
IBM today announced a new fixed-price offering for small and mid-sized businesses (SMBs) navigating government compliance mandates for the United States pharmaceutical industry.
The IBM BioPharmaceutical Solution helps pharmaceutical and biotech companies meet requirements of the Food and Drug Administration (FDA) and enables growing companies to make faster, more informed business decisions. The new industry-specific solution, delivered by IBM Business Consulting Services, consolidates information across different business processes to deliver an integrated reporting system.
The IBM BioPharmaceutical Solution is a qualified mySAP All-in-One solution, featuring a fixed price and a rapid implementation timeframe and leveraging open Linux technology, IBM DB2 Universal Database and IBM eServer and Storage technology. The total solution, which can be financed through IBM, is the latest addition to IBM's Express portfolio of offerings specifically priced and designed for the SMB marketplace.
Small and mid-sized pharmaceutical and biotech companies are often the source of innovative treatment techniques and need to move them to market quickly to help patients. However, these companies must comply with rigorous regulatory mandates put in place to protect consumers. Using industry-specific reporting capabilities, the IBM BioPharmaceutical Solution can help growing pharmaceutical and biotech companies comply with the FDA requirements outlined in 21 CFR Part 11.
The new solution leverages IBM Business Consulting Service's deep pharmaceutical industry experience and provides deployment with a preconfigured platform that offers small and mid-sized biotech and pharmaceutical companies a reliable and scalable foundation on which to build their business. This qualified mySAP All-in-One-solution from IBM is also available on other IBM platforms.
Other news from the department research and development
